Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 146 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Low Dose CT scan Clear all
Recruiting Phase 1 Interventional

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

NCT05711615
View directory record Official record
Conditions
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Myxofibrosarcoma, Unresectable Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Completed Phase 2 Interventional Results available

Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

NCT00941070
View directory record Official record
Conditions
Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity
Interventions
triapine, cisplatin, external beam radiation therapy, quality-of-life assessment, questionnaire administration, fludeoxyglucose F 18, positron emission tomography, computed tomography
Drug · Radiation · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Nov 15, 2026, 5:17 AM EST
Completed Not applicable Interventional

Development of Ultra-Low Dose CT Based Screening for Aortic Aneurysms

NCT03479164
View directory record Official record
Conditions
Aortic Aneurysm, Thoracic, Aortic Aneurysm, Abdominal
Interventions
Ultra Low-Dose CT
Other
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Nov 15, 2026, 5:17 AM EST
Completed Phase 2Phase 3 Interventional Results available

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

NCT02673151
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
Interventions
Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
Procedure · Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Nov 15, 2026, 5:17 AM EST
Terminated Not applicable Interventional Results available

FDG-PET in Advanced Melanoma

NCT02236546
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
[18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography, computed tomography
Diagnostic Test · Other · Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Nov 15, 2026, 5:17 AM EST
Completed Not applicable Interventional Results available

Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease

NCT00601146
View directory record Official record
Conditions
Lung Cancer
Interventions
chest computed tomography scan
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Nov 15, 2026, 5:17 AM EST
Terminated Early Phase 1 Interventional Accepts healthy volunteers

64Cu-LLP2A for Imaging Multiple Myeloma

NCT03804424
View directory record Official record
Conditions
Multiple Myeloma
Interventions
64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, PET/CT
Drug · Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Nov 15, 2026, 5:17 AM EST
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Ultralow Dose PET Imaging of 18F-flurpiridaz

NCT07284576
View directory record Official record
Conditions
Healthy Volunteer, Coronary Arterial Disease, Myocardial Ischemia, Myocardial Infarction
Interventions
18F-flurpiridaz
Drug
Lead sponsor
Akiva Mintz
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening

NCT02286713
View directory record Official record
Conditions
Lung Cancer, Smoking Cessation, Tobacco Use Cessation
Interventions
Patient Decision Aid, Standard Educational Information, Follow-Up Assessments: Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
55 Years to 77 Years
Enrollment
516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Ridgeland, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Nov 15, 2026, 5:17 AM EST
Terminated Not applicable Interventional

Validation of Low Dose CT for Diagnosis of Urolithiasis

NCT03656913
View directory record Official record
Conditions
Nephrolithiasis, Ureterolithiases
Interventions
Extremely low dose CT
Diagnostic Test
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 20 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Nov 15, 2026, 5:17 AM EST
Completed Phase 2 Interventional Results available

Lipoic Acid Supplement for Cystine Stone

NCT02910531
View directory record Official record
Conditions
Cystinuria
Interventions
Alpha lipoic acid, Placebo
Dietary Supplement · Drug
Lead sponsor
Thomas Chi, MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Recruiting Phase 2 Interventional

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

NCT05847569
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

Technology-Based Cancer Screening Intervention

NCT04535492
View directory record Official record
Conditions
Colorectal Cancer, Lung Cancer, Breast Cancer
Interventions
Decision Making Support Tool
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
50 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Nov 15, 2026, 5:17 AM EST
Completed Not applicable Interventional

Maine Lung Cancer Coalition: Using CHWs for the Annual Lung Cancer Screening Reminder

NCT04007458
View directory record Official record
Conditions
Lung Cancer
Interventions
Letter, Community Health Worker Phone Call
Behavioral
Lead sponsor
Anne Conners
Other
Eligibility
55 Years to 80 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Augusta, Maine
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Nov 15, 2026, 5:17 AM EST
Completed Not applicable Interventional Results available

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

NCT02609737
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
PET/CT Imaging, 68Ga-DOTA-JR11, 177Lu-DOTA-JR11
Device · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Nov 15, 2026, 5:17 AM EST
Recruiting Phase 1 Interventional

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

NCT07619599
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy
Procedure · Radiation · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Patient Navigation for Lung Screening at MGH Community Health Centers

NCT02705365
View directory record Official record
Conditions
Lung Cancer
Interventions
Patient Navigation, Usual Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 77 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Nov 15, 2026, 5:17 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Prospective Low Dose CT for Total Shoulder Arthroplasty/Reverse Shoulder Arthroplasty

NCT05350319
View directory record Official record
Conditions
Shoulder Arthroplasty
Interventions
A low-dose CT scan of the shoulder
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Nov 15, 2026, 5:17 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD

NCT06751576
View directory record Official record
Conditions
High Risk Cancer, Lung Cancer
Interventions
Median LCS
Device
Lead sponsor
Median Technologies
Industry
Eligibility
50 Years to 80 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Nov 15, 2026, 5:17 AM EST
Completed No phase listed Observational Accepts healthy volunteers

The Liver in the World Trade Center Health Program General Responder Cohort and Controls

NCT03858920
View directory record Official record
Conditions
Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
Interventions
Fibroscan of Liver, Low-dose non-contrast CT
Device · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Nov 15, 2026, 5:17 AM EST
Not listed Not applicable Interventional

Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT

NCT03519659
View directory record Official record
Conditions
PET/CT Imaging
Interventions
PET/CT scan with 13 mCi radiation dose, PET/CT scan with 5 mCi radiation dose, PET/CT scan with 2.5 mCi radiation dose, PET/CT Scan with 6.5 mCi radiation dose, PET/CT Scan with not yet determined radiation dose
Diagnostic Test
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Nov 15, 2026, 5:17 AM EST
Not yet recruiting Not applicable Interventional

LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol A

NCT07685028
View directory record Official record
Conditions
Family History of Lung Cancer
Interventions
CT scan, Sybil
Diagnostic Test · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 15, 2026, 5:17 AM EST
Completed Phase 2 Interventional

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A

NCT01858922
View directory record Official record
Conditions
Hodgkin Disease
Interventions
ABVE-PC, DECA
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Nov 15, 2026, 5:17 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Lung Cancer Screening in High-risk Black Individuals

NCT05898594
View directory record Official record
Conditions
Lung Cancer, Lung Carcinoma
Interventions
Low-dose Computed Tomography
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Nov 15, 2026, 5:17 AM EST